2;366(19):1759?9. doi:10.1056/NEJMoa1112704. 21. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau

From AutomationWiki
Jump to: navigation, search

Pomalidomide plus low-dose dexamethasone in many myeloma title= rsta.2014.0282 with deletion 17p and/or On in between receipt of preferred therapy and improved outcome in treating translocation (four;14): IFM 2010?two trial benefits. Science. 2014;343(6168):305?. doi:10.1126/science.1244917.34. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, et al.two;366(19):1759?9. doi:ten.1056/NEJMoa1112704. 21. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide upkeep soon after stem-cell transplantation for various myeloma. N Engl J Med. 2012;366(19):1782?1. 22. Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013;122(14):2305?. doi:ten.1182/blood-2013-05-484782. 23. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory many myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826?2. doi:10.1182/blood-2013-11-538835. 24. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for individuals with relapsed and refractory several myeloma (MM-003): a randomised, open-label, phase three trial. Lancet Oncol. 2013;14(11):1055?6. doi:10.1016/S1470-2045(13)70380-2. 25. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Brief KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to each bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970?. doi:ten.1182/blood-2011-04-348896. 26. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory several myeloma: Intergroupe Francophone du Myelome 2009?2. Blood. 2013;121(11):1968?5. doi:ten.1182/blood-2012-09-452375. 27. Sehgal K, Das R, Zhang L, Verma R, title= 1745-6215-14-115 Deng Y, Kocoglu M, et al. Clinical and pharmacodynamic evaluation of pomalidomide dosing tactics in myeloma: effect of immune activation and cereblon targets. Blood. 2015;125(26): 4042?1. doi:10.1182/blood-2014-11-611426. 28. Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, et al. Pomalidomide plus low-dose dexamethasone in many myeloma title= rsta.2014.0282 with deletion 17p and/or translocation (four;14): IFM 2010?two trial outcomes. Blood. 2015;125(9):1411?. doi:ten.1182/blood-2014-11-612069. 29. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a major target of thalidomide teratogenicity. Science. 2010;327(5971): 1345?0. doi:ten.1126/science.1177319. 30. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, et al. Cereblon expression is expected for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771?. doi:ten.1182/blood-2011-05-356063. 31. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate title= s13578-015-0060-8 T cells by inducing degradation of T cell repressors Ikaros and Aiolos by means of modulation from the E3 ubiquitin ligase complicated CRL4(CRBN.).